pre-IPO PHARMA

COMPANY OVERVIEW

Symphogen is a leading clinical late-stage antibody oncology-focused company with a differentiated monoclonal antibody, or mAb, mixture product pipeline with significant clinical potential and commercial opportunities. Their novel biologic approach is uniquely designed to address tumor diversity and resistance by combining multiple antibodies in a single drug product.


LOCATION

  • Ballerup, , Denmark
  • Somerville, NJ, USA

  • THERAPEUTIC AREAS

  • Infectious Disease
  • Oncology

  • WEBSITE

    http://www.symphogen.com/


    CAREER WEBSITE

    http://www.symphogen.com/careers/


    SOCIAL MEDIA


    INVESTORS

    danica-pension essex-woodlands genentech glide-healthcare ld lønmodtagernes-dyrtidsfond novo-holdings pka sunstone-capital takeda-ventures


    PRESS RELEASES


    Jun 27, 2022


    Jun 4, 2020

    Servier Completes the Acquisition of Symphogen English Français español Deutsch


    Apr 3, 2020

    Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its RandD pipeline


    Apr 3, 2020

    Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its RandD pipeline


    Aug 5, 2019

    Symphogen Selects TransPerfect’s TI GlobalLearn Learning Management System for Study Personnel Training


    For More Press Releases


    Google Analytics Alternative